Replies to post #40553 on Biotech Values

[DewDiligence]

Re: SemBioSys (from SI)

http://www.siliconinvestor.com/readmsg.aspx?msgid=23186613

>>
From: DewDiligence_on_SI
1/15/2007 6:29:40 PM
To: technetium

>Will plants compete -- what about glycosylation and protein folding and isolation?<

SBS claims that folding has been demonstrated to be identical to that of endogenous insulin.

Insulin is not glycosylated so that’s not an issue in this program.

By isolation I assume you mean isolation of the insulin gene from other crops. This remains at least a theoretical concern for all transgenic plants grown outdoors, but there are no special problems in this regard for the SBS insulin program.

SBS can grow their insulin-producing plants indoors. (That’s where the supplies used in clinical trials to date have been grown.) Growing indoors reduces the yield, but this can be mitigated to some degree with horticultural adjustments. Still, I doubt the company would pursue commercialization if all product were required to be grown indoors.
<<